RNA interference

March 26, 2026 Alnylam Awarded 2026 Scientific Impact Award by MassBio Alnylam was recognized by Mass Bio for its pioneering work in RNA interference and the development of RNAi therapeutics as an innovative new class of medicines. Read More ›

January 12, 2025 Alnylam's Kevin Fitzgerald, PhD on The Long Run Podcast - The Past and Future of RNAi Ther ... Alnylam Chief Scientific Officer, Kevin Fitzgerald, PhD recently spoke with Luke Timmerman of The Long Run podcast about the past & future of RNAi therapeutics Read More ›

The following content may not be associated with Alnylam Pharmaceuticals.

Links to all outside sites are provided as a reference for our visitors.

Alnylam Pharmaceuticals does not endorse and is not responsible for the content on sites that are not owned and operated by Alnylam Pharmaceuticals.

Proceed to Site

FOLLOW US